Rafael holdings continues to expand its management team with a highly experienced global biopharmaceutical executive to build a fully integrated cancer metabolism therapeutics company and announces inducement grant under nyse rule 303a.08

Newark, n.j., sept. 24, 2021 /prnewswire/ -- rafael holdings, inc., (nyse: rfl), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its barer institute and investment in rafael pharmaceuticals, inc., announced today the appointment of ashok marin, chief legal officer.
RFL Ratings Summary
RFL Quant Ranking